

Protalix BioTherapeutics, Inc.  
Form 8-K  
January 05, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): January 5, 2015**

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

**Florida**                                    **001-33357**                                    **65-0643773**  
**(State or other jurisdiction**                                    **(Commission File Number)**                                    **(IRS Employer**  
**of incorporation)**                                    **Identification No.)**

**2 Snunit Street**                                    **20100**  
**Science Park, POB 455**  
**Carmiel, Israel**  
**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition**

On January 5, 2015, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing the Company’s newly implemented strategy for accelerated growth. The release includes an estimate of the Company’s current cash position. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

**Item 8.01. Other Events**

As set forth in Item 2.02, on January 5, 2015, the Company issued a press release announcing its newly implemented strategy for accelerated growth.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated January 5, 2015 (disclosure referenced in Item. 2.02 is furnished with this report, not filed).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX  
BIOTHERAPEUTICS, INC.

Date: January 5, 2015 By: /s/ Moshe Manor  
Name: Moshe Manor  
Title: President and  
Chief Executive Officer